UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
၁၁၄.၄၆ US$
arrow_downward
-၀.၈၇%(-၁.၀၁) 1D
အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
၁၁၄.၉၅ US$
High
၁၁၅.၂၈ US$
Low
၁၁၄.၂၃ US$
Mkt. cap
ဋေ ၃.၉၄ ထ
Avg. vol.
၅.၃၃ သောင်း
Volume
၇.၀၆ သောင်း
52-wk high
၁၆၈.၇၆ US$
52-wk low
၁၁၀.၅၅ US$
Beta
၀.၅၇
Shares outstanding
၃၈.၉၀ ကုဋေ
No. of employees
၉ ထောင်
Open
၁၁၄.၉၅ US$
High
၁၁၅.၂၈ US$
Low
၁၁၄.၂၃ US$
Mkt. cap
ဋေ ၃.၉၄ ထ
Avg. vol.
၅.၃၃ သောင်း
Volume
၇.၀၆ သောင်း
52-wk high
၁၆၈.၇၆ US$
52-wk low
၁၁၀.၅၅ US$
Beta
၀.၅၇
Shares outstanding
၃၈.၉၀ ကုဋေ
No. of employees
၉ ထောင်
News stories
From web sources and news partners
TradingView
·
ပြီးခဲ့သည့် ၁ နာရီ
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
The Fintech Times
·
ပြီးခဲ့သည့် ၃၅ မိနစ်
First Digital to List on Nasdaq via SPAC Deal at $250m Valuation
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ နာရီ
Anthropic IPO Buzz Has Investors Watching Nasdaq Stock And ECM Fee Winners
Bloomberg.com
·
ပြီးခဲ့သည့် ၄ နာရီ
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR